Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Tramadol hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The name of your medicine is Zamadol® Capsules 50 mg (referred to as Zamadol throughout this leaflet). Zamadol contains tramadol hydrochloride which belongs to a group of medicines called opioids, which are 'pain relievers'. Tramadol interrupts the pain messages being sent to your brain, and it also acts in your brain to stop pain messages from being felt. This means that Zamadol does not stop the pain from happening, but you will not be able to feel the pain as much. This medicine has been prescribed for moderate to severe, a sudden or a long-standing pain (for example pain after an operation, or after an injury) in adults and adolescents aged 12 years and older. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your doctor should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.
e Zamadol Do not take Zamadol if:
•
you have taken more than prescribed dose of your sleeping tablets, antipsychotics, anti-depressants (antipsychotics and antidepressants are medicines that affect mood and emotions) or other pain killers, which can slow down your breathing and reactions.
Warnings and precautions Tolerance, dependence, and addiction This medicine contains tramadol which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Zamadol can also lead to dependence, abuse and addiction, which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Zamadol if:
Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Also, talk to your doctor or pharmacist before taking Zamadol, if:
•
•
• • • •
The pain relief effect of Zamadol may be weakened and/or shortened if you also take medicines containing:
Zamadol with food, drink and alcohol Zamadol should be taken with some water, with or without a meal. Avoid drinking alcohol while taking this medicine. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Please contact your doctor if you become pregnant during your treatment. Pregnancy Do not take Zamadol if you are pregnant or think you might be pregnant unless you have discussed this with your doctor and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Zamadol during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Breast-feeding Do not take Zamadol while you are breastfeeding as tramadol passes into breast milk and will affect your baby. Driving and using machines Even when taken according to instructions, Zamadol may impair the reactions of drivers, machine operators and workers without a safe hold. This effect may be potentiated by alcohol, at the beginning of treatment, when switching the drug, and on concomitant use of other CNS-depressants or antihistamines. If patients are affected they should be warned not to drive or operate machinery. The medicine can affect your ability to drive as it may make you sleepy or dizzy.
Zamadol Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The usual dose is 1 or 2 capsules every 4 to 6 hours. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Zamadol, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also section 2). Important: Your doctor will choose the dose that is right for you or your child. The dosage should be adjusted to the intensity of your pain and your individual pain sensitivity. In general, the lowest pain-relieving dose should be taken. The number of capsules to be taken will be shown clearly on the label that your pharmacist puts on the medicine. If it is not, or you are not sure, ask your doctor or pharmacist. To ensure safety for children, Zamadol capsules are packed in a child-resistant foil. The childresistant sealing foil is stronger, making it more difficult to push the capsules through. To avoid damaging the capsules when the capsule is pushed through the child-resistant sealing foil, pre-perforate the foil and then push the capsule out of the blister. Swallow the capsules whole with some water without chewing. If you have difficulty in swallowing, you may open the capsules. You must open them very carefully by pulling and twisting each end over a spoon so that all the pellets stay in the spoon. Do not chew. Swallow all the pellets with water. Dosage for adults and adolescents aged 12 years and older is: One or two Zamadol (equivalent to 50-100 mg tramadol hydrochloride). Depending on the pain, the effects lasts for about 4-8 hours. Your doctor may increase this dose up to 150-200 mg twice daily according to your needs. The maximum dose is usually 400 mg daily. Your prescribed daily dose will depend on the severity of your pain. Use in children: Zamadol should not be taken by children under 12 years of age. Use in elderly patients: In elderly patients (above 75 years of age) the excretion of tramadol may be delayed. If this applies to you, your doctor may recommend prolonging the dosage interval. Use in patients with severe liver or kidney disease (insufficiency)/dialysis patients: Patients with severe liver and/or kidney insufficiency should not take Zamadol. If in your case the insufficiency is mild or moderate, your doctor may recommend prolonging the dosage interval. Method of administration: Ask your doctor or pharmacist if:
Swallow the capsules whole with water without chewing. If you have difficulty in swallowing, your doctor may advise you to open the capsules. The capsules should be opened very carefully by pulling and twisting each end. The capsule should be opened over a spoon so that all the pellets stay in the spoon. The pellets should then be swallowed, take a sip of water afterwards to make sure that you have swallowed all the pellets. Remember that the pellets should not be chewed. If you take more Zamadol than you should If you accidentally take more tablets than your prescribed dose, tell your doctor or pharmacist immediately and if necessary contact your nearest hospital casualty department. Remember to take the pack and any remaining capsules with you. If you forget to take Zamadol Do not take a double dose to make up for a forgotten dose. If you stop taking Zamadol Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. Ask your doctor or pharmacist if:
Like all medicines, Zamadol can cause side effects, although not everybody gets them. The most serious side effects which may occur include allergic reaction (difficulty in breathing, wheezing and swelling of the face or throat), anaphylactic reaction (an extreme allergic reaction resulting in difficulty breathing, changes in heart rate, faintness, collapse or unconsciousness due to a drop in blood pressure) or convulsions (fits). If you have any of these symptoms you must stop taking Zamadol immediately and seek medical advice. Other side effects Very common (may affect more than 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
By reporting side effects, you can help provide more information on the safety of this medicine.
Zamadol • • • • • •
Do not store above 30°C. Keep this medicine out of the sight and reach of children. Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Keep your capsules in the original package. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Zamadol Capsules 50 mg contains: The active substance is tramadol hydrochloride. Each capsule contains 50 mg tramadol hydrochloride. The other ingredients are: calcium hydrogen phosphate, anhydrous, magnesium stearate, colloidal anhydrous silica, gelatin, titanium dioxide (E171), shellac, Iron oxide, black (E172), propylene glycol, ammonium hydroxide. What Zamadol Capsules 50 mg look like and contents of the pack The 50 mg Capsules are white in colour with black T 50 printing. All the capsules are packaged in blister strips of 10 capsules, with 1, 2, 3, 5, 6 or 10 blister strips in each carton. These presentations are not available in all countries. Marketing Authorisation Holder: Viatris Products Limited, Station Close, Potters Bar, EN6 1TL, United Kingdom. Manufacturer: Temmler Pharma GmbH Temmlerstrasse 2, 35039 Marburg, Germany This leaflet was last revised in 10/2025
Zamadol 50 mg Capsules comes as capsule containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Zamadol 50 mg Capsules is tramadol hydrochloride.
Medicines with the same active substance, strength and form include: Maxitram SR 50 mg prolonged-release capsule, Zamadol SR 50 mg Prolonged-release Hard Capsules, Zydol 50 mg Capsules. In total there are 9 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Zamadol 50 mg Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
For the treatment and prevention of moderate to severe pain.
Posology
The dose of Zamadol Capsules 50 mg should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected.
Dosage for adults and adolescents aged 12 years and older is:
For acute pain - an initial dose of 100 mg is usually necessary. This can be followed by doses of 50 mg or 100 mg not more frequently than 4 hourly, and duration of therapy should be matched to clinical need.
For pain associated with chronic conditions -use in an initial dose of 50 mg and then titrate dose according to pain severity. The need for continued treatment should be assessed at regular intervals as withdrawal symptoms and dependence have been reported, although rarely (see section 4.4)
A total oral daily dose of 400 mg should not be exceeded except in special clinical circumstances.
Paediatric population
Zamadol Capsules 50 mg should not be taken by children under 12 years of age, since safety and efficacy have not been established.
Elderly patients:
A dose adjustment is usually necessary in patients up to 75 years of age without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years of age elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
Patients with renal or hepatic impairment:
In patients with renal and/or hepatic insufficiency the elimination of Zamadol 50 mg capsules is delayed. In these patients prolongation of the dosage intervals should be carefully considered according to the patient's requirements.
• For creatinine clearance <30 ml/min the dosing should be increased to 12 hourly intervals.
• For creatinine clearance <10 ml/min (severe renal impairment) Zamadol 50 mg capsules is not recommended.
Tramadol is removed very slowly by haemodialysis or haemofiltration and therefore post-dialysis dosing to maintain analgesia is usually unnecessary.
Method of administration
The capsules are to be taken whole with sufficient liquid, independently of meals.
Swallow the capsules whole with some water without chewing.
If you have difficulty in swallowing, you may open the capsules. You must open them very carefully by pulling and twisting each end over a spoon so that all the pellets stay in the spoon. Do not chew. Swallow all the pellets with water.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with tramadol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Treatment goals and discontinuation
Before initiating treatment with Zamadol Capsules 50 mg, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with tramadol, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
- Hypersensitivity to the active substance tramadol hydrochloride or to any of the excipients listed in section 6.1.
- Acute intoxication with hypnotics, centrally acting analgesics, opioids, psychotropic drugs or alcohol.
- In common with other opioid analgesics, tramadol should not be administered to patients who are receiving monoamine oxidase inhibitors or within 2 weeks of their withdrawal.
- Uncontrolled epilepsy.
Tramadol must not be used for narcotic withdrawal treatment.
Serotonin syndrome
Serotonin syndrome, a potentially life-threatening condition, has been reported in patients receiving tramadol in combination with other serotonergic agents or tramadol alone (see sections 4.5, 4.8 and 4.9).
If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose escalations.
Symptoms of serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms. Withdrawal of the serotonergic drugs usually brings about a rapid improvement.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:
Concomitant use of Zamadol Capsules 50 mg and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Zamadol Capsules 50 mg concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Tolerance and opioid use disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as Zamadol Capsules 50 mg. Repeated use of Zamadol Capsules 50 mg can lead to opioid use disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Zamadol Capsules 50 mg may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with Zamadol Capsules 50 mg and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with tramadol.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
CYP2D6 metabolism:
Tramadol is metabolised by the liver enzyme CYP2D6. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect may not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an ultra-rapid metaboliser there is a risk of developing side effects of opioid toxicity even at commonly prescribed doses.
General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarised below:
Population
Prevalence %
African/Ethiopian
29%
African American
3.4% to 6.5%
Asian
1.2% to 2%
Caucasian
3.6% to 6.5%
Greek
6.0%
Hungarian
1.9%
Northern European
1% to 2%
Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit. Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. The risk of convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold (see section 4.5)
Adrenal insufficiency
Opioid analgesics may occasionally cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency may include e.g. severe abdominal pain, nausea and vomiting, low blood pressure, extreme fatigue, decreased appetite, and weight loss.
Paediatric population
Post-operative use in children
There have been reports in the published literature that tramadol given postoperatively in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnoea, led to rare, but life-threatening adverse events. Extreme caution should be exercised when tramadol is administered to children for post-operative pain relief and should be accompanied by close monitoring for symptoms of opioid toxicity including respiratory depression.
Children with compromised respiratory function
Tramadol is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures.
In patients with severe renal or hepatic impairment, head injury, increased intracranial pressure, or patients in shock or at risk of convulsions, Zamadol Capsules 50 mg should be used with caution.
At present Zamadol Capsules 50 mg should not be used during light planes of anaesthesia as enhanced intra-operative recall was reported in a study of the use of tramadol during anaesthesia with enflurane and nitrous oxide.
At therapeutic doses of tramadol respiratory depression has been reported infrequently. Therefore, care should be taken when administering Zamadol Capsules 50 mg to patients with existing respiratory depression or to patients taking concomitant CNS depressant drugs.
Patients treated with monoamine oxidase inhibitors within 14 days prior to administration of the opioid pethidine have experienced life-threatening interactions affecting the central nervous system as well as the respiratory and circulatory centres. The possibility of similar interactions occurring between monoamine oxidase inhibitors and tramadol cannot be ruled out.
Zamadol Capsules 50 mg may potentiate the CNS depressant effects of other centrally acting drugs (including alcohol) when administered concomitantly with such drugs.
The concomitant use of tramadol with sedative medicines such as benzodiazepines or related drugs including gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death because of additive CNS depressant effects. The dose and duration of concomitant use should be limited (see section 4.4).
Tramadol can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, anti-psychotics and other seizure threshold lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions (see section 4.4)
Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO-inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin syndrome, a potentially life-threatening condition (see sections 4.4 and 4.8).
Administration of Zamadol Capsules 50 mg together with carbamazepine results in markedly decreased serum concentrations of tramadol which may reduce analgesic effectiveness and shorten the duration of action.
Theoretically, tramadol could interact with noradrenaline, 5-HT or lithium, due to their mechanisms of action, and thus potentiate their anti-depressant effect. However there have been no reports of such interactions.
Caution should be exercised during concomitant treatment with tramadol and coumarin derivatives (e.g. warfarin) due to reports of increased INR and ecchymoses in some patients.
Pregnancy:
Zamadol Capsules 50 mg should not be used in pregnancy, as there is inadequate evidence available to assess the safety of tramadol in pregnant women. Studies of tramadol in rats and rabbits have revealed no teratogenic effects. However, embryotoxicity was shown in the form of delayed ossification. Fertility, reproductive performance and development of offspring were unaffected.
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breast-feeding:
Approximately 0.1% of the maternal dose of tramadol may be secreted in breast milk. In the immediate post-partum period, for maternal oral daily dosage up to 400 mg, this corresponds to a mean amount of tramadol ingested by breast-fed infants of 3% of the maternal weight-adjusted dosage. For this reason, administration to nursing women is not recommended as tramadol may cause respiratory depression I the infant. Alternatively, breast-feeding should be discontinued during treatment with tramadol. Discontinuation of breastfeeding is generally not necessary following a single dose of tramadol.
Zamadol Capsules 50 mg may cause drowsiness and this effect may be potentiated by alcohol and other CNS depressants. Patients should be warned not to drive or operate machinery.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
- The medicine has been prescribed to treat a medical or dental problem and
- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
- It was not affecting your ability to drive safely
Gastrointestinal disorders:
Very common (≥1/10): nausea
Common (≥1/100 to <1/10): vomiting, dry mouth and constipation.
Nervous system disorders:
Very common (≥1/10): dizziness
Common (≥1/100 to <1/10): headache and drowsiness
Rare (≥1/10,000 to <1/1,000) syncope, somnolence, and parasthesia have been reported. Epileptiform convulsions have been reported occurring mainly after administration of high doses of tramadol or after treatment with drugs which can lower the seizure threshold or themselves induce cerebral convulsions (e.g. anti-depressants or anti-psychotics).
Not known: Serotonin syndrome
Psychiatric disorders:
Rare (≥1/10,000 to <1/1,000): confusion, hallucinations, dysphoria, nightmares
Frequency not known (cannot be estimated from the available data): Drug dependence (see section 4.4).
General disorders and administration site conditions:
Uncommon (≥1/1,000 to <1/100): drug withdrawal syndrome (withdrawal reactions including agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms have been reported) (see sections 4.2 and 4.4)
Rare (≥1/10,000 to <1/1,000): fatigue
Eye disorders:
Rare (≥1/10,000 to <1/1,000): blurred vision
Respiratory, thoracic and mediastinal disorders:
Rare (≥1/10,000 to <1/1,000): respiratory depression
Frequency unknown: Hiccups
Immune system disorders:
Rare (≥1/10,000 to <1/1,000) allergic reactions (dyspnoea, wheezing, bronchospasm and worsening of asthma) and anaphylaxis have been reported.
Cardiac disorders:
Uncommon (≥1/1,000 to <1/100): palpitations, tachycardia
Rare (≥1/10,000 to <1/1,000): bradycardia
Vascular disorders:
Uncommon (≥1/1,000 to <1/100): orthostatic hypotension, flushing
Rare (≥1/10,000 to <1/1,000): hypertension
Metabolism and nutrition disorders:
Frequency not known (cannot be estimated from the available data): hypoglycaemia, hyponatraemia.
Skin and subcutaneous tissue disorders:
Common (≥1/100 to <1/10): sweating
Rare (≥1/10,000 to <1/1,000): Pruritus, urticaria and skin rashes have been reported.
Renal and urinary system disorders:
Rare (≥1/10,000 to <1/1,000): micturition disorders
Blood and lymphatic system disorders:
There have also been cases of blood dyscrasias observed with tramadol treatment, but direct causality has not been confirmed.
Hepatobiliary disorders:
In a few isolated cases increases in liver enzyme values have been reported concurrently with the therapeutic use of tramadol.
Drug dependence
Repeated use of Zamadol Capsules 50 mg can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms of tramadol overdose include vomiting, miosis, sedation, coma, seizures, cardiovascular collapse and respiratory depression. Such symptoms are typical of opioid analgesics.
Serotonin syndrome has also been reported.
Treatment of overdose requires the maintenance of the airway and cardiovascular functions. Respiratory depression may be reversed using naloxone and fits controlled with diazepam.
The treatment of acute overdose of tramadol using haemodialysis or haemofiltration alone is not sufficient or suitable due to the slow elimination of tramadol from the serum by these routes.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Ask anything about Zamadol 50 mg Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.